U.S. flag

An official website of the United States government

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Links from MedGen

Items: 1 to 20 of 321

1.
MAP2K1 K57N Conferred an Acquired Resistance to Furmonertinib, Dabrafenib and Trametinib Combined Therapy in Advanced Lung Adenocarcinoma with EGFR Mutation and BRAF V600E
Xiang Tan, Zuotao Wu, Mingwu Chen
Onco Targets Ther. 2024; 17: 307–312. Published online 2024 Apr 9. doi: 10.2147/OTT.S454902
PMCID:
PMC11015836
ArticlePDF–3.4M
2.
Apatinib plus chemotherapy is associated with an improved tumor response, survival and tolerance compared with chemotherapy alone for advanced lung adenocarcinoma treatment
Hua Ye, Wenwen Yu, Yangyang Ni, Xiaoqiong Bao, Xie Zhang, Yunlei Li, Ali Chen, Jifa Li, Long Zheng
Oncol Lett. 2024 May; 27(5): 194. Published online 2024 Mar 5. doi: 10.3892/ol.2024.14327
PMCID:
PMC10941069
ArticlePDF–2.4M
3.
Severe megaloblastic anemia in a patient with advanced lung adenocarcinoma during treatment with erlotinib: a case report and literature review
Xin Yan, Jingxian Kong, Jiacheng Wang, Caixia Wang, Hongchang Shen
BMC Pulm Med. 2024; 24: 121. Published online 2024 Mar 6. doi: 10.1186/s12890-024-02935-9
PMCID:
PMC10919028
ArticlePDF–650K
4.
The prognosis of TP53 and EGFR co-mutation in patients with advanced lung adenocarcinoma and intracranial metastasis treated with EGFR-TKIs
Weiguo Gu, Penghui Liu, Jiaming Tang, Jianfei Lai, Siya Wang, Jiaming Zhang, Jinbiao Xu, Jianxiong Deng, Feng Yu, Chao Shi, Feng Qiu
Front Oncol. 2023; 13: 1288468. Published online 2024 Feb 5. doi: 10.3389/fonc.2023.1288468
PMCID:
PMC10875041
ArticlePDF–2.8M
5.
Effective treatment of advanced lung adenocarcinoma with paraneoplastic leukemoid reaction with Lorlatinib: a case report
Ruiqi Niu, Yiruo Zhang, Jingdan Pang, Qing Zhou, Yu Lei, Yingying Du
Front Oncol. 2024; 14: 1341233. Published online 2024 Jan 26. doi: 10.3389/fonc.2024.1341233
PMCID:
PMC10853376
ArticlePDF–1.4M
6.
Clinical Response of Advanced Lung Adenocarcinoma with Class III BRAF G466V Missense Mutation to Dabrafenib and Trametinib: A Case Report
Ruoxin Fang, Sha Xu, Jun Gong, Zhengkai Liao
Onco Targets Ther. 2024; 17: 27–31. Published online 2024 Jan 23. doi: 10.2147/OTT.S448132
PMCID:
PMC10821729
ArticlePDF–2.4M
7.
Retinal Metastases as the Initial Presentation of Advanced Lung Adenocarcinoma
Catarina Oliveira-Silva, Maria Manuel Pereira, Catarina Ferreira, Eduardo Macedo, Marta Mendes, Ana Rita Marques, Ilídio Brandão
Eur J Case Rep Intern Med. 2024; 11(1): 004190. Published online 2023 Dec 13. doi: 10.12890/2023_004190
PMCID:
PMC10783458
ArticlePDF–657K
8.
First report of furmonertinib as a first-line treatment in advanced lung adenocarcinoma patients harboring EGFR exon 20 insertion mutations after the kinase domain αC-helix: Two case reports and a literature review
Huan Han, Xiao Zhang, Xiao Liu, Jiuzhou Zhao, Jianbo Zhang, Jianwei Zhang, Hui Zhu, Shuyue Jiao, Hong Tang
Medicine (Baltimore) 2023 Dec 29; 102(52): e36667. Published online 2023 Dec 29. doi: 10.1097/MD.0000000000036667
PMCID:
PMC10754557
ArticlePDF–1.5M
9.
Single-cell RNA-sequencing uncovers the dynamic changes of tumour immune microenvironment in advanced lung adenocarcinoma
Haijiao Lu, Jialin Qian, Lei Cheng, Yinchen Shen, Tianqing Chu, Chaoxian Zhao
BMJ Open Respir Res. 2023; 10(1): e001878. Published online 2023 Dec 11. doi: 10.1136/bmjresp-2023-001878
PMCID:
PMC10729175
ArticlePDF–5.7M
10.
Stevens–Johnson syndrome induced by toripalimab in a previously EGFR-TKI-treated advanced lung adenocarcinoma patient harboring EGFR mutations 19 del/T790M/C797S in trans and cis: a case report
Yang Chen, Hanhan Hong, Shujun Bao, Hao Tang
Front Pharmacol. 2023; 14: 1131703. Published online 2023 Nov 14. doi: 10.3389/fphar.2023.1131703
PMCID:
PMC10682071
ArticlePDF–1.4M
11.
A real-world study and network pharmacology analysis of EGFR-TKIs combined with ZLJT to delay drug resistance in advanced lung adenocarcinoma
Xue Han, Lan Liang, Chenming He, Qinyou Ren, Jialin Su, Liang Cao, Jin Zheng
BMC Complement Med Ther. 2023; 23: 422. Published online 2023 Nov 21. doi: 10.1186/s12906-023-04213-3
PMCID:
PMC10664478
ArticlePDF–6.8M
12.
Clinicopathological characteristics correlated with programmed cell death-ligand 1 expression in advanced lung adenocarcinoma
Hengxing Gao, Xuexue Zou, Jing Wang, Jiejun Zhou, Meng Fan, Mingwei Chen
J Thorac Dis. 2023 Oct 31; 15(10): 5307–5318. Published online 2023 Sep 11. doi: 10.21037/jtd-23-523
PMCID:
PMC10636434
ArticlePDF–770K
13.
Risk factors for symptomatic malignant pleural effusion recurrence in patients with actionable mutations in advanced lung adenocarcinoma
Ke Xu, Xiaodi Wu, Lu Chen, Jingyuan Xie, Xin Hua, Mo Chen, Yuxin Jiang, Hongbing Liu, Fang Zhang, Tangfeng Lv, Yong Song, Ping Zhan
Transl Lung Cancer Res. 2023 Sep 28; 12(9): 1887–1895. Published online 2023 Sep 1. doi: 10.21037/tlcr-23-151
PMCID:
PMC10579833
ArticlePDF–224K
14.
Therapeutic impact of epidermal growth factor receptor tyrosine kinase inhibitor with various treatment combinations for advanced lung adenocarcinoma
Ying-Yi Chen, Kuan-Hsun Lin, Yen-Shou Kuo, Yuan-Ming Tsai, Hsu-Kai Huang, Tsai-Wang Huang
World J Surg Oncol. 2023; 21: 326. Published online 2023 Oct 13. doi: 10.1186/s12957-023-03203-6
PMCID:
PMC10571456
ArticlePDF–1.5M
15.
Thyroid transcription factor 1 (TTF‐1) negativity as a predictor of unfavorable response to EGFR‐TKI therapy in advanced lung adenocarcinoma patients with EGFR mutations
Xiaosheng Ding, Weiwei Shi, Bingxuan Han, Hanxiao Chen, Jia Li, Juan An, Lili Zhou, Weiran Xu, Hui Shi, Xixi Zheng, Yichun Hua, Xiaoyan Li
Thorac Cancer. 2023 Oct; 14(29): 2934–2940. Published online 2023 Aug 22. doi: 10.1111/1759-7714.15079
PMCID:
PMC10569904
ArticlePDF–1013K
16.
Long-term survival of advanced lung adenocarcinoma by maintenance chemotherapy followed by EGFR-TKI: A case report
Hui Jun Chen, Ji Min Shen, Ying Ni Lin, Wei Du, Jian Ping Zhou, Qing Yun Li
Medicine (Baltimore) 2021 Feb 12; 100(6): e24688. Published online 2021 Feb 12. doi: 10.1097/MD.0000000000024688
PMCID:
PMC10545137
ArticlePDF–811K
17.
Case Report: sintilimab-induced Stevens-Johnson Syndrome in a patient with advanced lung adenocarcinoma
Xueqin Li, Guanghui Li, Diangang Chen, Linxi Su, Ru-peng Wang, Yi Zhou
Front Oncol. 2023; 13: 912168. Published online 2023 Sep 14. doi: 10.3389/fonc.2023.912168
PMCID:
PMC10540079
ArticlePDF–5.0M
18.
Association between Contrast-Enhanced Computed Tomography Radiomic Features, Genomic Alterations and Prognosis in Advanced Lung Adenocarcinoma Patients
Lisa Rinaldi, Elena Guerini Rocco, Gianluca Spitaleri, Sara Raimondi, Ilaria Attili, Alberto Ranghiero, Giulio Cammarata, Marta Minotti, Giuliana Lo Presti, Francesca De Piano, Federica Bellerba, Gianluigi Funicelli, Stefania Volpe, Serena Mora, Cristiana Fodor, Cristiano Rampinelli, Massimo Barberis, Filippo De Marinis, Barbara Alicja Jereczek-Fossa, Roberto Orecchia, Stefania Rizzo, Francesca Botta
Cancers (Basel) 2023 Sep; 15(18): 4553. Published online 2023 Sep 14. doi: 10.3390/cancers15184553
PMCID:
PMC10527057
ArticlePDF–539K
19.
Novel PPFIA1-ALK, ALK-C2orf91(intergenic) double-fusion responded well to alectinib in an advanced lung adenocarcinoma patient: a case report
Lingxin Yan, Jiayu Zheng, Qingyun Pan, Yuxian Liang, Pengli Yu, Quanfang Chen
Front Oncol. 2023; 13: 1264820. Published online 2023 Aug 29. doi: 10.3389/fonc.2023.1264820
PMCID:
PMC10497211
ArticlePDF–5.2M
20.
Case Report: ALK rearranged locally advanced lung adenocarcinoma showing inconsistent radiographic findings and pathological responses during neoadjuvant alectinib therapy
Peijun Cao, Qingchun Zhao, Yongwen Li, Ruifeng Shi, Guangsheng Zhu, Zihe Zhang, Hongbing Zhang, Minghui Liu, Sen Wei, Hongyu Liu, Jun Chen
Front Pharmacol. 2023; 14: 1140894. Published online 2023 Aug 17. doi: 10.3389/fphar.2023.1140894
PMCID:
PMC10470069
ArticlePDF–2.6M

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Filter your results:

Find related data

Recent activity

Clear Turn Off Turn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
You are here: NCBI > Literature > PubMed Central (PMC)
Support Center